ARQ 197

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cirrhosis

Conditions

Cirrhosis, Hepatocellular Carcinoma

Trial Timeline

Jan 1, 2009 → Dec 1, 2011

NCT ID

NCT00802555

About ARQ 197

ARQ 197 is a phase 1 stage product being developed by Merck for Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00802555. Target conditions include Cirrhosis, Hepatocellular Carcinoma.

What happened to similar drugs?

6 of 11 similar drugs in Cirrhosis were approved

Approved (6) Terminated (0) Active (5)

✅Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved

✅Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)NovartisApproved

✅Telbivudine + Enecavir + AdefovirNovartisApproved

✅abataceptBristol Myers SquibbApproved

✅losartan (drug)LundbeckApproved

✅AlbuminGrifolsApproved

🔄peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00802555	Phase 1	Completed	Jan 1, 2009	Dec 1, 2011	Cirrhosis
NCT00658554	Phase 1	Completed	Apr 1, 2008	Jun 1, 2008	Healthy
NCT00612703	Phase 1	Completed	Feb 1, 2008	—	Cancer
NCT00557609	Phase 2	Completed	Oct 1, 2007	Feb 1, 2011	Renal Cell Carcinoma (RCC)
NCT00612209	Phase 1	Completed	Apr 1, 2007	Feb 1, 2010	Cancer, Advanced Solid Tumors
NCT00302172	Phase 1	Completed	Jan 1, 2006	—	Cancer

Competing Products

20 competing products in Cirrhosis

See all competitors

Product	Company	Stage	Hype Score
SYNB1020	Synlogic	Phase 1/2	14
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin	Chugai Pharmaceutical	Phase 3	40
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)	Shionogi	Phase 2	35
Mesenchymal Stem Cell	Rohto Pharmaceutical	Pre-clinical	26
Bumetanide + Furosemide	Johnson & Johnson	Phase 3	47
Mesenchymal stem cell	Rohto Pharmaceutical	Phase 1/2	32
Zibotentan	AstraZeneca	Phase 1	29
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozin	AstraZeneca	Phase 2	27
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin	AstraZeneca	Phase 2	35
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV	Merck	Approved	39
Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)	Novartis	Approved	43
Telbivudine + Enecavir + Adefovir	Novartis	Approved	39
Serelaxin + Placebo	Novartis	Phase 2	35
Terlipressin acetate + Serelaxin (RLX030)	Novartis	Phase 2	35
Pasireotide	Novartis	Phase 1	29
HPN-100 + Placebo	Amgen	Phase 2	35
Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mg	Gilead Sciences	Phase 2	27
TDF/FTC/LPV/r + Placebo	Gilead Sciences	Pre-clinical	18
MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg Capsule	Gilead Sciences	Phase 2	35
Seladelpar 5 mg Capsule + Seladelpar 10 mg Capsule	Gilead Sciences	Phase 3	44